Drugmakers Tackle Biosimilars Oversight At FTC Forum
Amgen Inc., Sandoz Inc. and other drugmakers locked horns Tuesday at a Federal Trade Commission forum examining state-level restrictions on pharmacy substitution of biosimilars and whether the copycat medicines should have...To view the full article, register now.
Already a subscriber? Click here to view full article